



an Open Access Journal by MDPI

# **Breast Cancer Brain Metastasis and Leptomeningeal Disease**

Guest Editors:

Dr. Albert Grinshpun

Dr. Nancy U. Lin

submissions:

#### Message from the Guest Editors

malignancy. About one in five patients with metastatic Dr. Sarah Sammons breast cancer will develop brain metastases (BMs) during their disease course. Specifically, HER2-positive and triplenegative breast cancer subtypes have higher incidences of BMs, with recent data suggesting an increase in the overall incidence of MBC-related BMs in Western countries. Deadline for manuscript Historically, BMs were associated with poor prognoses: however, novel approaches and therapies are starting to 15 September 2024 change the paradigm in patients with MBC-related BMs. Furthermore. BMs from metastatic breast cancer were found to have unique clinical and molecular features when compared to other tumor types, highlighting the need for

> Our goal in the current Special Issue of Cancers is to shed light on the latest advancements in this perplexing field and raise awareness of the most significant contemporary challenges in the diagnosis, monitoring, treatment, and prognostication of patients with metastatic breast cancer and BMs

further specific investment and research in this field.

Brain metastases are the most common intracranial



**Special**sue





an Open Access Journal by MDPI

## **Editor-in-Chief**

#### Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions. **High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases. **Journal Rank:** JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

## **Contact Us**

*Cancers* Editorial Office MDPI, St. Alban-Anlage 66 4052 Basel, Switzerland Tel: +41 61 683 77 34 www.mdpi.com mdpi.com/journal/cancers cancers@mdpi.com X@Cancers\_MDPI